Top

Virology Journal

Published in:

01-12-2021 | Hepatitis B | Review

Advances in HBV infection and replication systems in vitro

Authors: Ruirui Xu, Pingping Hu, Yuwen Li, Anran Tian, Jun Li, Chuanlong Zhu

Published in: Virology Journal | Issue 1/2021

Abstract

Background

Hepatitis B virus (HBV) is a DNA virus belonging to the Hepadnaviridae family that has limited tissue and species specificity. Due to the persistence of HBV covalently closed circular DNA (cccDNA) in host cells after HBV infection, current antiviral drugs cannot eradicate HBV. Therefore, the development of an active cell culture system supporting HBV infection has become the key to studying HBV and developing effective therapeutic drugs.

Main body

This review summarizes the significant research achievements in HBV cell culture systems in vitro, including embryonic hepatocytes and primary hepatocytes, which support the virus infection process most similar to that in the body and various liver tumor cells. The discovery of the bile-acid pump sodium-taurocholate co-transporting polypeptide (NTCP) as the receptor of HBV has advanced our understanding of HBV biology. Subsequently, various liver cancer cells overexpressing NTCP that support HBV infection have been established, opening a new door for studying HBV infection. The fact that induced pluripotent stem cells that differentiate into hepatocyte-like cells support HBV infection provides a novel idea for the establishment of an HBV cell culture system.

Conclusion

Because of the host and tissue specificity of HBV, a suitable in vitro HBV infection system is critical for the study of HBV pathogenesis. Nevertheless, recent advances regarding HBV infection in vitro offer hope for better studying the biological characteristics of HBV, the pathogenesis of hepatitis B, the screening of anti-HBV drugs and the mechanism of carcinogenesis.

Asabe S, Wieland SF, Chattopadhyay PK, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol. 2009;83(19):9652–62. https://doi.org/10.1128/jvi.00867-09].CrossRefPubMedPubMedCentral

Cheng PN, Liu WC, Tsai HW, et al. Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. J Med Virol. 2011;83(4):602–7. https://doi.org/10.1002/jmv.22014.CrossRefPubMed

Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972–84. https://doi.org/10.1136/gutjnl-2015-309809.CrossRefPubMed

Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005;42(3):302–8. https://doi.org/10.1016/j.jhep.2004.12.015.CrossRefPubMed

Gripon P, Diot C, Theze N, et al. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol. 1988;62(11):4136–43.CrossRefPubMedPubMedCentral

Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A. 1987;84(4):1005–9.CrossRefPubMedPubMedCentral

Sells MA, Zelent AZ, Shvartsman M, et al. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol. 1988;62(8):2836–44.CrossRefPubMedPubMedCentral

Ladner SK, Otto MJ, Barker CS, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother. 1997;41(8):1715–20.CrossRefPubMedPubMedCentral

Guo H, Jiang D, Zhou T, et al. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol. 2007;81(22):12472–84. https://doi.org/10.1128/jvi.01123-07.CrossRefPubMedPubMedCentral

10.

Cai D, Mills C, Yu W, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother. 2012;56(8):4277–88. https://doi.org/10.1128/aac.00473-12.CrossRefPubMedPubMedCentral

11.

Cai D, Wang X, Yan R, et al. Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators. Antiviral Res. 2016;132:26–37. https://doi.org/10.1016/j.antiviral.2016.05.005.CrossRefPubMedPubMedCentral

12.

Iwamoto M, Cai D, Sugiyama M, et al. Functional association of cellular microtubules with viral capsid assembly supports efficient hepatitis B virus replication. Sci Rep. 2017;7(1):10620. https://doi.org/10.1038/s41598-017-11015-4.CrossRefPubMedPubMedCentral

13.

Sprinzl MF, Oberwinkler H, Schaller H, et al. Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier. J Virol. 2001;75(11):5108–18. https://doi.org/10.1128/jvi.75.11.5108-5118.2001.CrossRefPubMedPubMedCentral

14.

Hofmann C, Sandig V, Jennings G, et al. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci U S A. 1995;92(22):10099–103.CrossRefPubMedPubMedCentral

15.

Bramson JL, Graham FL, Gauldie J. The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr Opin Biotechnol. 1995;6(5):590–5.CrossRefPubMed

16.

Li Q, Kay MA, Finegold M, et al. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther. 1993;4(4):403–9. https://doi.org/10.1089/hum.1993.4.4-403.CrossRefPubMed

17.

Delaney WEt, Miller TG, Isom HC. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (−)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chemother 1999; 43(8): 2017–26

18.

Delaney WET, Isom HC. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 1998; 28(4): 1134-46. doi: https://doi.org/10.1002/hep.510280432

19.

Abdelhamed AM, Kelley CM, Miller TG, et al. Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment. J Virol. 2002;76(16):8148–60.CrossRefPubMedPubMedCentral

20.

Boyce FM, Bucher NL. Baculovirus-mediated gene transfer into mammalian cells. Proc Natl Acad Sci U S A. 1996;93(6):2348–52.CrossRefPubMedPubMedCentral

21.

Hofmann C, Strauss M. Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Ther. 1998;5(4):531–6. https://doi.org/10.1038/sj.gt.3300607.CrossRefPubMed

22.

Ochiya T, Tsurimoto T, Ueda K, et al. An in vitro system for infection with hepatitis B virus that uses primary human fetal hepatocytes. Proc Natl Acad Sci U S A. 1989;86(6):1875–9.CrossRefPubMedPubMedCentral

23.

Lin M, Chen Q, Yang LY, et al. Hepatitis B virus infection and replication in primarily cultured human fetal hepatocytes. World J Gastroenterol. 2007;13(7):1027–31. https://doi.org/10.3748/wjg.v13.i7.1027.CrossRefPubMedPubMedCentral

24.

Lázaro CA, Croager EJ, Mitchell C, et al. Establishment, characterization, and long-term maintenance of cultures of human fetal hepatocytes. Hepatology. 2003;38(5):1095–106. https://doi.org/10.1053/jhep.2003.50448.CrossRefPubMed

25.

Zhou M, Zhao F, Li J, et al. Long-term maintenance of human fetal hepatocytes and prolonged susceptibility to HBV infection by co-culture with non-parenchymal cells. J Virol Methods. 2014;195:185–93. https://doi.org/10.1016/j.jviromet.2013.10.010.CrossRefPubMed

26.

Schulze-Bergkamen H, Untergasser A, Dax A, et al. Primary human hepatocytes: a valuable tool for investigation of apoptosis and hepatitis B virus infection. J Hepatol. 2003;38(6):736–44.CrossRefPubMed

27.

Rijntjes PJ, Moshage HJ, Van Gemert PJ, et al. Cryopreservation of adult human hepatocytes. The influence of deep freezing storage on the viability, cell seeding, survival, fine structures and albumin synthesis in primary cultures. J Hepatol 1986; 3(1): 7-18

28.

Galle PR, Hagelstein J, Kommerell B, et al. In vitro experimental infection of primary human hepatocytes with hepatitis B virus. Gastroenterology. 1994;106(3):664–73. https://doi.org/10.1016/0016-5085(94)90700-5.CrossRefPubMed

29.

Katsura N, Ikai I, Mitaka T, et al. Long-term culture of primary human hepatocytes with preservation of proliferative capacity and differentiated functions. J Surg Res. 2002;106(1):115–23.CrossRefPubMed

30.

Gripon P, Diot C, Guguen-Guillouzo C. Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration. Virology. 1993;192(2):534–40. https://doi.org/10.1006/viro.1993.1069.CrossRefPubMed

31.

Ishida Y, Yamasaki C, Yanagi A, et al. Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice. Am J Pathol. 2015;185(5):1275–85. https://doi.org/10.1016/j.ajpath.2015.01.028.CrossRefPubMed

32.

Ulvestad M, Darnell M, Molden E, et al. Evaluation of organic anion-transporting polypeptide 1B1 and CYP3A4 activities in primary human hepatocytes and HepaRG cells cultured in a dynamic three-dimensional bioreactor system. J Pharmacol Exp Ther. 2012;343(1):145–56. https://doi.org/10.1124/jpet.112.195750.CrossRefPubMed

33.

Bhatia SN, Balis UJ, Yarmush ML, et al. Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. Faseb J. 1999;13(14):1883–900.CrossRefPubMed

34.

Malik R, Selden C, Hodgson H. The role of non-parenchymal cells in liver growth. Semin Cell Dev Biol. 2002;13(6):425–31.CrossRefPubMed

35.

Kasuya J, Sudo R, Mitaka T, et al. Hepatic stellate cell-mediated three-dimensional hepatocyte and endothelial cell triculture model. Tissue Eng Part A. 2011;17(3–4):361–70. https://doi.org/10.1089/ten.TEA.2010.0033.CrossRefPubMed

36.

Fu GB, Huang WJ, Zeng M, et al. Expansion and differentiation of human hepatocyte-derived liver progenitor-like cells and their use for the study of hepatotropic pathogens. Cell Res. 2019;29(1):8–22. https://doi.org/10.1038/s41422-018-0103-x.CrossRefPubMed

37.

Zhang K, Zhang L, Liu W, et al. In vitro expansion of primary human hepatocytes with efficient liver repopulation capacity. Cell Stem Cell. 2018;23(6):806-819.e4. https://doi.org/10.1016/j.stem.2018.10.018.CrossRefPubMed

38.

Peng WC, Logan CY, Fish M, et al. Inflammatory cytokine TNFalpha promotes the long-term expansion of primary hepatocytes in 3D culture. Cell. 2018;175(6):1607–19. https://doi.org/10.1016/j.cell.2018.11.012.CrossRefPubMedPubMedCentral

39.

Hu H, Gehart H, Artegiani B, et al. Long-term expansion of functional mouse and human hepatocytes as 3D organoids. Cell. 2018;175(6):1591–606. https://doi.org/10.1016/j.cell.2018.11.013.CrossRefPubMed

40.

Tostões RM, Leite SB, Serra M, et al. Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing. Hepatology. 2012;55(4):1227–36. https://doi.org/10.1002/hep.24760.CrossRefPubMed

41.

Lauschke VM, Shafagh RZ, Hendriks DFG, et al. 3D primary hepatocyte culture systems for analyses of liver diseases, drug metabolism, and toxicity: emerging culture paradigms and applications. Biotechnol J. 2019;14(7):e1800347. https://doi.org/10.1002/biot.201800347.CrossRefPubMed

42.

Vorrink SU, Ullah S, Schmidt S, et al. Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics. Faseb J. 2017;31(6):2696–708. https://doi.org/10.1096/fj.201601375R.CrossRefPubMedPubMedCentral

43.

Sohlenius-Sternbeck AK, Jones C, Ferguson D, et al. Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. Xenobiotica. 2012;42(9):841–53. https://doi.org/10.3109/00498254.2012.669080.CrossRefPubMed

44.

Wood FL, Houston JB, Hallifax D. Importance of the unstirred water layer and hepatocyte membrane integrity in vitro for quantification of intrinsic metabolic clearance. Drug Metab Dispos. 2018;46(3):268–78. https://doi.org/10.1124/dmd.117.078949.CrossRefPubMed

45.

Hutzler JM, Ring BJ, Anderson SR. Low-turnover drug molecules: a current challenge for drug metabolism scientists. Drug Metab Dispos. 2015;43(12):1917–28. https://doi.org/10.1124/dmd.115.066431.CrossRefPubMed

46.

Hegde M, Jindal R, Bhushan A, et al. Dynamic interplay of flow and collagen stabilizes primary hepatocytes culture in a microfluidic platform. Lab Chip. 2014;14(12):2033–9. https://doi.org/10.1039/c4lc00071d.CrossRefPubMedPubMedCentral

47.

Fernandes R, Luo X, Tsao CY, et al. Biological nanofactories facilitate spatially selective capture and manipulation of quorum sensing bacteria in a bioMEMS device. Lab Chip. 2010;10(9):1128–34. https://doi.org/10.1039/b926846d.CrossRefPubMed

48.

Atienzar FA, Novik EI, Gerets HH, et al. Predictivity of dog co-culture model, primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humans. Toxicol Appl Pharmacol. 2014;275(1):44–61. https://doi.org/10.1016/j.taap.2013.11.022.CrossRefPubMed

49.

Bonn B, Svanberg P, Janefeldt A, et al. Determination of human hepatocyte intrinsic clearance for slowly metabolized compounds: comparison of a primary hepatocyte/stromal cell co-culture with plated primary hepatocytes and HepaRG. Drug Metab Dispos. 2016;44(4):527–33. https://doi.org/10.1124/dmd.115.067769.CrossRefPubMed

50.

Winer BY, Huang TS, Pludwinski E, et al. Long-term hepatitis B infection in a scalable hepatic co-culture system. Nat Commun. 2017;8(1):125. https://doi.org/10.1038/s41467-017-00200-8.CrossRefPubMedPubMedCentral

51.

Walter E, Keist R, Niederost B, et al. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology. 1996;24(1):1–5. https://doi.org/10.1002/hep.510240101.CrossRefPubMed

52.

Glebe D, Aliakbari M, Krass P, et al. Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol. 2003;77(17):9511–21.CrossRefPubMedPubMedCentral

53.

Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049. https://doi.org/10.7554/eLife.00049.CrossRefPubMedPubMedCentral

54.

Xu G, Gao Z, He W, et al. microRNA expression in hepatitis B virus infected primary treeshrew hepatocytes and the independence of intracellular miR-122 level for de novo HBV infection in culture. Virology. 2014;448:247–54. https://doi.org/10.1016/j.virol.2013.10.016.CrossRefPubMed

55.

Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A. 2002;99(24):15655–60. https://doi.org/10.1073/pnas.232137699.CrossRefPubMedPubMedCentral

56.

Schulze A, Mills K, Weiss TS, et al. Hepatocyte polarization is essential for the productive entry of the hepatitis B virus. Hepatology. 2012;55(2):373–83. https://doi.org/10.1002/hep.24707.CrossRefPubMed

57.

Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol. 2005;79(3):1613–22. https://doi.org/10.1128/jvi.79.3.1613-1622.2005.CrossRefPubMedPubMedCentral

58.

Marion MJ, Hantz O, Durantel D. The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies. Methods Mol Biol. 2010;640:261–72. https://doi.org/10.1007/978-1-60761-688-7_13.CrossRefPubMed

59.

Aninat C, Piton A, Glaise D, et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos. 2006;34(1):75–83. https://doi.org/10.1124/dmd.105.006759.CrossRefPubMed

60.

Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72. https://doi.org/10.1016/j.cell.2007.11.019.CrossRefPubMed

61.

Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–20. https://doi.org/10.1126/science.1151526.CrossRefPubMed

62.

Si-Tayeb K, Noto FK, Nagaoka M, et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology. 2010;51(1):297–305. https://doi.org/10.1002/hep.23354.CrossRefPubMed

63.

Kaneko S, Kakinuma S, Asahina Y, et al. Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus. Sci Rep. 2016;6:29358. https://doi.org/10.1038/srep29358.CrossRefPubMedPubMedCentral

64.

Sakurai F, Mitani S, Yamamoto T, et al. Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection. Sci Rep. 2017;7:45698. https://doi.org/10.1038/srep45698.CrossRefPubMedPubMedCentral

65.

Xia Y, Carpentier A, Cheng X, et al. Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions. J Hepatol. 2017;66(3):494–503. https://doi.org/10.1016/j.jhep.2016.10.009.CrossRefPubMed

66.

Nie YZ, Zheng YW, Miyakawa K, et al. Recapitulation of hepatitis B virus-host interactions in liver organoids from human induced pluripotent stem cells. EBioMedicine. 2018;35:114–23. https://doi.org/10.1016/j.ebiom.2018.08.014.CrossRefPubMedPubMedCentral

67.

Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology. 2007;46(6):1759–68. https://doi.org/10.1002/hep.21896.CrossRefPubMed

68.

Barrera A, Guerra B, Notvall L, et al. Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition. J Virol. 2005;79(15):9786–98. https://doi.org/10.1128/jvi.79.15.9786-9798.2005.CrossRefPubMedPubMedCentral

69.

Glebe D, Urban S, Knoop EV, et al. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology. 2005;129(1):234–45.CrossRefPubMed

70.

Engelke M, Mills K, Seitz S, et al. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology. 2006;43(4):750–60. https://doi.org/10.1002/hep.21112.CrossRefPubMed

71.

Urban S, Gripon P. Inhibition of duck hepatitis B virus infection by a myristoylated pre-S peptide of the large viral surface protein. J Virol. 2002;76(4):1986–90.CrossRefPubMedPubMedCentral

72.

Ni Y, Lempp FA, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014;146(4):1070–83. https://doi.org/10.1053/j.gastro.2013.12.024.CrossRefPubMed

73.

Stieger B, Hagenbuch B, Landmann L, et al. In situ localization of the hepatocytic Na+/Taurocholate cotransporting polypeptide in rat liver. Gastroenterology. 1994;107(6):1781–7.CrossRefPubMed

74.

Claro da Silva T, Polli JE, Swaan PW. The solute carrier family 10 (SLC10): beyond bile acid transport. Mol Aspects Med 2013; 34(2–3): 252-69. DOI: https://doi.org/10.1016/j.mam.2012.07.004

75.

Stieger B. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb Exp Pharmacol 2011: 205–259 DOI: https://doi.org/10.1007/978-3-642-14541-4_5

76.

Yan H, Peng B, He W, et al. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol. 2013;87(14):7977–91. https://doi.org/10.1128/jvi.03540-12.CrossRefPubMedPubMedCentral

77.

Watashi K, Sluder A, Daito T, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology. 2014;59(5):1726–37. https://doi.org/10.1002/hep.26982.CrossRefPubMed

78.

Nkongolo S, Ni Y, Lempp FA, et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol. 2014;60(4):723–31. https://doi.org/10.1016/j.jhep.2013.11.022.CrossRefPubMed

79.

Tsukuda S, Watashi K, Iwamoto M, et al. Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression. J Biol Chem. 2015;290(9):5673–84. https://doi.org/10.1074/jbc.M114.602540.CrossRefPubMed

80.

Mutz P, Metz P, Lempp FA, et al. HBV bypasses the innate immune response and does not protect HCV from antiviral activity of interferon. Gastroenterology. 2018;154(6):1791-1804.e22. https://doi.org/10.1053/j.gastro.2018.01.044.CrossRefPubMed

81.

Watashi K, Urban S, Li W, et al. NTCP and beyond: opening the door to unveil hepatitis B virus entry. Int J Mol Sci. 2014;15(2):2892–905. https://doi.org/10.3390/ijms15022892.CrossRefPubMedPubMedCentral

82.

Saso W, Tsukuda S, Ohashi H, et al. A new strategy to identify hepatitis B virus entry inhibitors by AlphaScreen technology targeting the envelope-receptor interaction. Biochem Biophys Res Commun. 2018;501(2):374–9. https://doi.org/10.1016/j.bbrc.2018.04.187.CrossRefPubMed

83.

Miyakawa K, Matsunaga S, Yamaoka Y, et al. Development of a cell-based assay to identify hepatitis B virus entry inhibitors targeting the sodium taurocholate cotransporting polypeptide. Oncotarget. 2018;9(34):23681–94. https://doi.org/10.18632/oncotarget.25348.CrossRefPubMedPubMedCentral

84.

Kaneko M, Futamura Y, Tsukuda S, et al. Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide. Sci Rep. 2018;8(1):2769. https://doi.org/10.1038/s41598-018-20987-w.CrossRefPubMedPubMedCentral

85.

Choijilsuren G, Jhou RS, Chou SF, et al. Heparin at physiological concentration can enhance PEG-free in vitro infection with human hepatitis B virus. Sci Rep. 2017;7(1):14461. https://doi.org/10.1038/s41598-017-14573-9.CrossRefPubMedPubMedCentral

86.

König A, Yang J, Jo E, et al. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells. J Hepatol. 2019;71(2):289–300. https://doi.org/10.1016/j.jhep.2019.04.010.CrossRefPubMed

87.

Michailidis E, Pabon J, Xiang K, et al. A robust cell culture system supporting the complete life cycle of hepatitis B virus. Sci Rep. 2017;7(1):16616. https://doi.org/10.1038/s41598-017-16882-5.CrossRefPubMedPubMedCentral

88.

Li K, Chen Z, Kato N, et al. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem. 2005;280(17):16739–47. https://doi.org/10.1074/jbc.M414139200.CrossRefPubMed

89.

Tnani M, Bayard BA. Evidence for IRF-1-dependent gene expression deficiency in interferon unresponsive HepG2 cells. Biochim Biophys Acta. 1999;1451(1):59–72.CrossRefPubMed

90.

Li GQ, Xu WZ, Wang JX, et al. Combination of small interfering RNA and lamivudine on inhibition of human B virus replication in HepG2.2.15 cells. World J Gastroenterol 2007; 13(16): 2324–7 DOI: https://doi.org/10.3748/wjg.v13.i16.2324

91.

Indrasetiawan P, Aoki-Utsubo C, Hanafi M, et al. Antiviral activity of cananga odorata against hepatitis B virus. Kobe J Med Sci. 2019;65(2):E71-e79.PubMedPubMedCentral

92.

Yang PL, Althage A, Chung J, et al. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A. 2002;99(21):13825–30. https://doi.org/10.1073/pnas.202398599.CrossRefPubMedPubMedCentral

93.

Lucifora J, Vincent IE, Berthillon P, et al. Hepatitis B virus replication in primary macaque hepatocytes: crossing the species barrier toward a new small primate model. Hepatology. 2010;51(6):1954–60. https://doi.org/10.1002/hep.23602.CrossRefPubMed

94.

Wang F, Zhang X, Zhang J, et al. Effect of fibronectin on HBV infection in primary human fetal hepatocytes in vitro. Mol Med Rep. 2012;6(5):1145–9. https://doi.org/10.3892/mmr.2012.1029.CrossRefPubMed

95.

Rose KA, Holman NS, Green AM, et al. Co-culture of hepatocytes and Kupffer Cells as an in vitro model of inflammation and drug-induced hepatotoxicity. J Pharm Sci. 2016;105(2):950–64. https://doi.org/10.1016/s0022-3549(15)00192-6.CrossRefPubMedPubMedCentral

96.

Baumert TF, Yang C, Schürmann P, et al. Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes. Hepatology. 2005;41(2):247–56. https://doi.org/10.1002/hep.20553.CrossRefPubMed

97.

Shlomai A, Schwartz RE, Ramanan V, et al. Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. Proc Natl Acad Sci U S A. 2014;111(33):12193–8. https://doi.org/10.1073/pnas.1412631111.CrossRefPubMedPubMedCentral

98.

Gómez-Lechón MJ, Tolosa L. Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening. Arch Toxicol. 2016;90(9):2049–61. https://doi.org/10.1007/s00204-016-1756-1.CrossRefPubMed

99.

Iwamoto M, Watashi K, Tsukuda S, et al. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem Biophys Res Commun. 2014;443(3):808–13. https://doi.org/10.1016/j.bbrc.2013.12.052.CrossRefPubMed

Title: Advances in HBV infection and replication systems in vitro
Authors: Ruirui Xu
Pingping Hu
Yuwen Li
Anran Tian
Jun Li
Chuanlong Zhu
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Hepatitis B
Published in: Virology Journal / Issue 1/2021
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/s12985-021-01580-6

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Advances in HBV infection and replication systems in vitro

Abstract

Background

Main body

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Main body

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Evolutionary trajectory of SARS-CoV-2 and emerging variants

In vitro and in vivo analyses of co-infections with peste des petits ruminants and capripox vaccine strains

3C protease of enterovirus 71 cleaves promyelocytic leukemia protein and impairs PML-NBs production

One-step real-time multiplex reverse transcription-polymerase chain reaction assay with melt curve analysis for detection of potato leafroll virus, potato virus S, potato virus X, and potato virus Y

Development of genus-specific universal primers for the detection of flaviviruses

Roles of two distinct alphasatellites modulating geminivirus pathogenesis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page